A Phase 2 interventional study of Met DR and Met XR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 82nd largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2013, is one of 23 in phase 2, and was the 174th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Elcelyx Therapeutics, Inc. has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and tolerability of a range of doses of Met DR when administered in subjects with type 2 diabetes mellitus (T2DM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Was male, or if female and met all of the following criteria:
Either was not treated with or had been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to Visit 1:
Exclusion Criteria:
Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
Had been treated, was being treated, or was expected to require or undergo treatment with any of the following excluded medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 mg delayed-release metformin once daily in the morning
Drug: Met DR
800 mg delayed-release metformin once daily in the morning
Drug: Met DR
1000 mg delayed-release metformin once daily in the morning
Drug: Met DR
1000 mg extended-release metformin once daily in the evening
Drug: Met XR
2000 mg extended-release metformin once daily in the evening
Drug: Met XR
Placebo once daily in the morning
Drug: Placebo
Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks
Time frame: Baseline and 4 weeks after the first dose of study medication
AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks
Time frame: Baseline and 4 to 12 weeks after the first dose of study medication
Change in HbA1c (%) at 12 Weeks
Time frame: Baseline and 12 weeks after the first dose of study medication
| Milestone | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| Started | 41 | 39 | 40 | 40 | 40 | 40 |
| Completed | 35 | 36 | 37 | 35 | 36 | 33 |
| Not completed | 6 | 3 | 3 | 5 | 4 | 7 |
| Withdrew: Adverse event | 1 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 0 | 1 | 2 | 1 | 0 | 1 |
| Withdrew: Loss of glucose control | 2 | 1 | 0 | 1 | 2 | 0 |
| mg/dL | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks | -4 (-69 to 48) | -11 (-124 to 150) | -13 (-62 to 145) | -18 (-90 to 113) | -12 (-111 to 58) | -25 (-110 to 20) |
| mg/dL*week | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks | 4.00 (-784.0 to 698.0) | -96.00 (-894.0 to 414.0) | -108.00 (-556.0 to 612.0) | -156.00 (-782.0 to 522.0) | -98.00 (-880.0 to 314.0) | -215.00 (-856.0 to 186.0) |
| HbA1c (%) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| Change in HbA1c (%) at 12 Weeks | 0.45 ± 0.137 | -0.03 ± 0.125 | 0.00 ± 0.121 | 0.10 ± 0.124 | 0.00 ± 0.132 | -0.21 ± 0.133 |
Collected over Approximately 83 to 107 days depending on the number of intervening days between study visits. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/41 (0%) | 9/41 (22%) |
| 600 mg DR | — | 1/39 (2.6%) | 9/39 (23.1%) |
| 800 mg DR | — | 0/40 (0%) | 11/40 (27.5%) |
| 1000 mg DR | — | 2/40 (5%) | 9/40 (22.5%) |
| 1000 mg XR | — | 1/40 (2.5%) | 8/40 (20%) |
| 2000 mg XR | — | 0/40 (0%) | 8/40 (20%) |
| Event | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| Hyperglycaemic hyperosmolar nonketotic syndromeMetabolism and nutrition disorders | 0/41 | 1/39 | 0/40 | 0/40 | 0/40 | 0/40 |
| Kidney infectionInfections and infestations | 0/41 | 0/39 | 0/40 | 1/40 | 0/40 | 0/40 |
| Intravascular haemolysisBlood and lymphatic system disorders | 0/41 | 0/39 | 0/40 | 1/40 | 0/40 | 0/40 |
| LeukocytosisBlood and lymphatic system disorders | 0/41 | 0/39 | 0/40 | 1/40 | 0/40 | 0/40 |
| Non-cardiac chest painGeneral disorders | 0/41 | 0/39 | 0/40 | 0/40 | 1/40 | 0/40 |
| Event | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/41 | 3/39 | 1/40 | 5/40 | 2/40 | 2/40 |
| DizzinessNervous system disorders | 2/41 | 0/39 | 2/40 | 1/40 | 2/40 | 3/40 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/41 | 2/39 | 2/40 | 0/40 | 1/40 | 1/40 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/41 | 2/39 | 1/40 | 1/40 | 1/40 | 0/40 |
| NauseaGastrointestinal disorders | 0/41 | 0/39 | 1/40 | 0/40 | 2/40 | 1/40 |
| ConstipationGastrointestinal disorders | 0/41 | 1/39 | 2/40 | 0/40 | 0/40 | 0/40 |
| Abdominal DistensionGastrointestinal disorders | 0/41 | 0/39 | 0/40 | 0/40 | 2/40 | 0/40 |
| SinusitisInfections and infestations | 0/41 | 1/39 | 0/40 | 2/40 | 1/40 | 1/40 |
| BronchitisInfections and infestations | 0/41 | 0/39 | 0/40 | 2/40 | 2/40 | 0/40 |
| NasopharyngitisInfections and infestations | 2/41 | 0/39 | 2/40 | 0/40 | 0/40 | 0/40 |
ITT Population
| Age, Continuous(years) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 51.4 ± 10.22 | 53.5 ± 8.34 | 52.6 ± 9.69 | 51.8 ± 9.05 | 51.0 ± 9.62 | 52.0 ± 9.53 | 52.0 ± 9.37 |
| Sex: Female, Male(Participants) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Female | 22 | 21 | 27 | 14 | 22 | 21 | 127 |
| Male | 19 | 18 | 13 | 26 | 18 | 19 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 17 | 14 | 10 | 14 | 10 | 10 | 75 |
| Not Hispanic or Latino | 24 | 25 | 30 | 26 | 30 | 30 | 165 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 1 | 0 | 3 | 0 | 2 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 11 | 9 | 13 | 9 | 14 | 12 | 68 |
| White | 28 | 30 | 23 | 30 | 24 | 27 | 162 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| BMI(kg/m²) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33.6 ± 5.28 | 33.1 ± 5.74 | 33.5 ± 5.86 | 33.3 ± 5.55 | 32.8 ± 5.27 | 33.7 ± 5.22 | 33.3 ± 5.44 |
| Previous T2DM Regimen(participants) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Diet and exercise alone | 3 | 7 | 2 | 4 | 6 | 5 | 27 |
| DPP-4 inhibitor alone | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Metformin alone | 35 | 29 | 35 | 36 | 30 | 33 | 198 |
| Metformin/DPP-4 inhibitor combination | 3 | 2 | 3 | 0 | 4 | 2 | 14 |
| Screening Fasting Plasma Glucose(mg/dL) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 146.5 ± 36.70 | 147.5 ± 42.56 | 142.4 ± 34.60 | 141.4 ± 29.79 | 139.0 ± 34.22 | 148.9 ± 41.36 | 144.3 ± 36.57 |
| Screening HbA1c(%) | Placebo | 600 mg DR | 800 mg DR | 1000 mg DR | 1000 mg XR | 2000 mg XR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 7.19 ± 0.838 | 7.27 ± 0.864 | 7.17 ± 0.829 | 7.13 ± 0.899 | 7.10 ± 0.819 | 7.17 ± 0.869 | 7.17 ± 0.846 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Apr 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Elcelyx Therapeutics, Inc.